Projected Benefits of Long-Acting Antiretroviral Therapy in Nonsuppressed People With Human Immunodeficiency Virus Experiencing Adherence Barriers

BACKGROUND: In a demonstration project, long-acting, injectable cabotegravir-rilpivirine (CAB-RPV) achieved viral suppression in a high proportion of people with HIV (PWH) who were virologically nonsuppressed with adherence barriers. We projected the long-term impact of CAB-RPV for nonsuppressed PWH...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Wanyi, Gandhi, Monica, Sax, Paul E, Neilan, Anne M, Garland, Wendy H, Wilkin, Timothy, Cohen, Rebecca, Ciaranello, Andrea L, Kulkarni, Sonali P, Eron, Joseph, Freedberg, Kenneth A, Hyle, Emily P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439527/
https://www.ncbi.nlm.nih.gov/pubmed/37601728
http://dx.doi.org/10.1093/ofid/ofad390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439527/
https://www.ncbi.nlm.nih.gov/pubmed/37601728
http://dx.doi.org/10.1093/ofid/ofad390

Ejemplares similares